摘要
類風濕性關節炎（rheumatoid arthritis, RA）是種全身性、慢性發炎的自體免疫疾病，會引起滑膜發炎（synovial inflammation），造成關節變形，甚至導致失能而影響日常生活。Janus kinase（JAK）激酶抑制劑是種新型的標靶合成型的疾病修飾抗風濕藥物（targeted synthetic DMARDs, tsDMARDs），透過抑制細胞內的JAK激酶來減少發炎反應，可用於治療難治型的類風濕性關節炎，且效果良好，唯近年來有越來越多的證據顯示其可能有的副作用，如嚴重感染、心血管及癌症等。本篇針對此議題作進一步的探討與分析。
參考文獻
Tanaka Y, Luo Y, O'Shea JJ, et al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 2022;18:133-45.
Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022;386:316-26.
Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 2021;80:71-87.
Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009;10:356-60.
O'Sullivan LA, Liongue C, Lewis RS, et al. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 2007;44:2497-506.